Results from US research suggest that clonal hematopoiesis of indeterminate potential (CHIP) is significantly and independently associated with the risk of cardiovascular disease (CVD) in patients with multiple myeloma (MM) undergoing hematopoietic cell transplantation (HCT). According to the researchers, CHIP can serve as a new biomarker for CVD in this setting.
The aim of this retrospective cohort study was to investigate the association between CHIP and CVD in patients with MM who underwent HCT between 2010 and 2016 and for whom peripheral blood stem cells (PBSC, pre-HCT) were available. In addition, factors influencing CVD risk in patients with CHIP were described. The primary endpoint was the 5-year cumulative incidence of de novo CVD (heart failure, coronary artery disease, or stroke) after HCT.
Of 1036 patients with MM (56% were male; median age 60.0 years) who underwent initial autologous HCT, 201 had at least 1 CHIP variant (19.4%) and 35 patients had 2 or more variants ( 3.4%). The 5-year incidence of CVD was significantly higher in patients with CHIP compared to patients without CHIP (21.1% versus 8.4%; p < 0.001); the 5-year incidence among patients with 2 or more variants was 25.6%. In multivariate analysis, CHIP was associated with an increased risk of CVD in general (HR 2.72; 95% CI 1.70-4.39), as well as with specific conditions, including heart failure (HR 4.02; 95% CI CI 2.32-6.98), coronary artery disease (HR 2.22; 95% CI 1.06-4.63) and stroke (HR 3.02; 95% CI 1.07-8.52) . Patients who had both CHIP and pre-existing hypertension or dyslipidemia had an almost 7-fold and 4-fold increased risk of CVD, respectively, compared to patients without CHIP, hypertension, or dyslipidemia.
Bron:
2024-01-24 08:07:57
#Clonal #hematopoiesis #CVD #patients #undergoing #HCT #MedNet
